Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced the voluntary withdrawal of its drug registration...

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Fineline Cube Jul 30, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the marketing authorization application...

Company Drug

Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares

Fineline Cube Jul 30, 2026

Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced that its Category 1 therapeutic biologic HB0034...

Company Drug

CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma

Fineline Cube Jul 30, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that CRB-701 (SYS 6002), a next-generation antibody-drug conjugate...

Company Drug

Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention

Fineline Cube Jul 30, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its novel selective neurokinin-1...

Company Drug

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Fineline Cube Jul 30, 2026

Akeso, Inc. (HKG: 9926) and Shanghai Allink Biotherapeutics Inc. announced a clinical research collaboration to...

Company Drug

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Fineline Cube Jul 29, 2026

Guangzhou Innogen Pharmaceutical Group Co., Ltd. (HKG: 2591) announced plans to initiate a Phase Ib...

Company Drug

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Fineline Cube Jul 29, 2026

Ribo Life Science (HKG: 6938) announced that its small interfering RNA (siRNA) therapy vortosiran (BD4059)...

Company Drug

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Fineline Cube Jul 29, 2026

Hansoh Pharmaceutical (HKG: 3692) announced that its pivotal Phase III ARTEMIS-011 clinical trial of Risvutatug...

Company Drug

Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial

Fineline Cube Jul 29, 2026

Shionogi & Co., Ltd. (TYO: 4507) announced the U.S. commercial availability of XOCOVA (ensitrelvir), an...

Company Drug

Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma

Fineline Cube Jul 29, 2026

Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company’s...

Company Drug

Humanwell Healthcare’s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials

Fineline Cube Jul 29, 2026

Humanwell Healthcare (SHA: 600079) announced that its novel drug candidate HW243040 has received clinical trial...

Company Drug

AstraZeneca’s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data

Fineline Cube Jul 29, 2026

AstraZeneca plc (NYSE: AZN) announced that its ALXN1210-TMA-313 Phase III clinical trial failed to meet...

Company Drug

Changchun High-Tech Industries Subsidiary GenSci Advances Graves’ Disease Therapy to Phase II with US Partner Yarrow Bioscience

Fineline Cube Jul 29, 2026

Changchun High-Tech Industries (Group) Co., Ltd. (SHE: 000661) announced that its subsidiary GenSci has initiated...

Company Drug

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Fineline Cube Jul 28, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class...

Company Drug

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jul 28, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its innovative antibody-drug conjugate...

Company Drug

CSPC’s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status

Fineline Cube Jul 28, 2026

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase III clinical trial of its...

Company Drug

Fosun Pharma’s DM1001 Receives NMPA Clearance for Parkinson’s Disease Clinical Trials

Fineline Cube Jul 28, 2026

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical...

Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Fineline Cube Jul 28, 2026

InnoCare Pharma (HKG: 9969) announced that the pivotal Phase III clinical trial of its potent,...

Company Drug

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

Fineline Cube Jul 28, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that HRS-1780 tablets have received...

Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares

CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma

Hengrui Pharmaceuticals Secures NMPA Approval for HRS5580 Long-Acting NK-1 Antagonist in Combination Therapy for Postoperative Nausea and Vomiting Prevention

Akeso and Allink Biotherapeutics Launch Phase II Trial of PD-1/VEGF-FGFR2b ADC Combination for Squamous NSCLC Following NMPA IND Approval

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership

Shionogi Launches XOCOVA (Ensitrelvir) in US for COVID-19 Post-Exposure Prophylaxis Following 67% Risk Reduction in Global Trial

Insilico Medicine’s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma

Humanwell Healthcare’s Non-Opioid Analgesic HW243040 Receives NMPA Approval for Peripheral Neuropathic Pain Clinical Trials

AstraZeneca’s Ultomiris Fails Primary Endpoint in Adult HSCT-TMA Phase III Trial Despite Positive Pediatric Data

Changchun High-Tech Industries Subsidiary GenSci Advances Graves’ Disease Therapy to Phase II with US Partner Yarrow Bioscience

CSPC’s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor

Hengrui’s Tissue Factor-Targeting ADC SHR-4375 Receives FDA Orphan Drug Designation for Pancreatic Cancer

CSPC’s Novel SNRI Ammuxetine Meets Primary Endpoint in Phase III Depression Trial, Poised for First-Line Status

Fosun Pharma’s DM1001 Receives NMPA Clearance for Parkinson’s Disease Clinical Trials

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

You Missed

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares